Analyst Ratings For Juno Therapeutics (NASDAQ:JUNO)
Today, Wells Fargo & Co reiterated its Market Perform rating on Juno Therapeutics (NASDAQ:JUNO) with a price target of $63.00.
Some recent analyst ratings include
- 1/17/2018-Wells Fargo & Co Reiterated Rating of Market Perform.
- 1/11/2018-Raymond James Financial Reiterated Rating of Buy.
- 1/11/2018-JPMorgan Chase & Co. Reiterated Rating of Hold.
- 1/5/2018-Needham & Company LLC initiated coverage with a Buy rating.
- 11/3/2017-Cowen Reiterated Rating of Buy.
- 11/2/2017-Leerink Swann Reiterated Rating of Outperform .
Recent Insider Trading Activity For Juno Therapeutics (NASDAQ:JUNO)
Juno Therapeutics (NASDAQ:JUNO) has insider ownership of 15.08% and institutional ownership of 69.94%.
- On 1/8/2018 Richard Klausner, Director, sold 12,724 with an average share price of $48.21 per share and the total transaction amounting to $613,424.04.
- On 12/21/2017 Richard Klausner, Director, sold 36,000 with an average share price of $44.76 per share and the total transaction amounting to $1,611,360.00.
- On 12/21/2017 Steve Harr, CFO, sold 8,750 with an average share price of $44.76 per share and the total transaction amounting to $391,650.00.
- On 12/18/2017 Robert Azelby, EVP, sold 1,816 with an average share price of $44.96 per share and the total transaction amounting to $81,647.36.
- On 11/2/2017 Robert Azelby, EVP, sold 6,666 with an average share price of $54.95 per share and the total transaction amounting to $366,296.70.
- On 10/2/2017 Sunil Agarwal, Insider, sold 7,285 with an average share price of $44.76 per share and the total transaction amounting to $326,076.60.
- On 9/14/2017 Bernard J Cassidy, General Counsel, sold 28,000 with an average share price of $44.92 per share and the total transaction amounting to $1,257,760.00.
Recent Trading Activity for Juno Therapeutics (NASDAQ:JUNO)
Shares of Juno Therapeutics closed the previous trading session at 66.22 up +20.62 45.23% with shares trading hands.
